Dangerous liaisons: flirtations between oncogenic BRAF and GRP78 in drug-resistant melanomas

Area of Science:

• Oncology
• Molecular Biology
• Cellular Stress Response

Background:

• BRAF mutations drive aggressive melanoma, leading to kinase activation.
• BRAF inhibitors like vemurafenib show efficacy but are limited by rapid acquired resistance.
• Understanding resistance mechanisms is crucial for improving melanoma treatment strategies.

Purpose of the Study:

• To investigate the mechanisms of vemurafenib resistance in BRAF(V600E) melanoma.
• To explore the role of ER stress and autophagy in acquired resistance to BRAF inhibitors.
• To evaluate the therapeutic potential of combining BRAF inhibitors with autophagy inhibitors.

Main Methods:

• Utilized preclinical melanoma models with BRAF(V600E) mutations.
• Assessed the impact of vemurafenib on ER stress and autophagy pathways.
• Investigated the interaction between mutant BRAF, GRP78, and PERK signaling.
• Evaluated the efficacy of combination therapy with vemurafenib and autophagy inhibitors in resistant melanoma models.

Main Results:

• Vemurafenib treatment induced ER stress and autophagy in BRAF(V600E) melanoma cells.
• Mutant BRAF sequestered the ER chaperone GRP78, leading to PERK activation.
• Combination therapy of vemurafenib and an autophagy inhibitor significantly reduced tumor burden in preclinical models of vemurafenib-resistant melanoma.

Conclusions:

• ER stress and autophagy represent a key resistance mechanism to vemurafenib in BRAF(V600E) melanoma.
• Targeting autophagy in combination with BRAF inhibition offers a promising strategy to overcome treatment resistance.
• Further clinical studies are warranted to validate these findings and establish combination therapy efficacy in melanoma patients.